Dec 30, 2019
Does anyone else have an unhealthy love of euler’s idenetity????
seen from Germany
seen from Germany
seen from China
seen from Hong Kong SAR China
seen from United States
seen from Malta
seen from Malaysia
seen from China
seen from Australia
seen from United States
seen from United States
seen from China
seen from United States
seen from United States
seen from Singapore
seen from United States
seen from Singapore
seen from China
seen from Argentina
seen from Ukraine
Does anyone else have an unhealthy love of euler’s idenetity????
Were you interested in my ACR presentation but unable to attend?
I’m excited to share that I’ll be speaking in a EULAR webinar in June titled "Disrupting the Status Quo: Advancing LGBTQIA+ Inclusion in Rheumatology Practice and Research."
In this session, I’ll be sharing more about my own experience navigating rheumatology care as a queer & trans person living in a rural area of a red state in the U.S. — and what that has meant in practice: access barriers, safety concerns, gaps in provider knowledge, and the emotional labor that too often comes with simply trying to receive competent care.
This webinar won’t just focus on lived experience. My colleagues and I will also be speaking about what best practice actually looks like, in clinic as well as in research spaces — because equity has to show up in both the exam room and the evidence base.
If you’re a clinician, researcher, advocate, patient, or someone working to improve access and outcomes in rheumatology, I hope you’ll join us.
UCB is ready to present bimekizumab’s results from BE MOBILE 1 for non-radiographic axial spondyloarthritis (nr-axSpA), BE MOBILE 2 for ankylosing spondylitis (AS), and BE COMPELTE study for psoriatic arthritis (PsA).
Guselkumab, migliora la sintomatologia articolare e cutanea dell'artrite psoriasica
Guselkumab migliora diversi outcomes clinici, in pazienti adulti con artrite psoriasica attiva.
Sono i nuovi dati a 52 settimane degli studi clinici di fase 3, DISCOVER-1 e DISCOVER-2, presentati da Janssen, azienda farmaceutica del gruppo Johnson & Johnson, allo European League Against Rheumatism E-Congress 2020 (eEULAR 2020), e riguardano il miglioramento dei sintomi articolari e cutanei,…
View On WordPress
Rheumatologische Versorgung soll durch virtuelles Forschungszentrum verbessert werden
http://dlvr.it/RXzfRp
‘Romatolojide Hedef 2020 Sempozyumu’, 18-21 Mart 2020 tarihlerinde CVK Park Bosphorus Hotel’de gerçekleştirilecektir. Ayrıntılı bilgi almak için, Web: www.hedefromatoloji.org E-mail: [email protected] #deventsocial #romatoloji #romatoidartrit #artrit #eular #romatizma #tedaviyöntemleri #ankilozanspondilit #kongre #sempozyum #toplantı #mice #event #workshop #cvkparkbosphorus #istanbul (D Event Tourism Organization) https://www.instagram.com/p/B9ZVXfoHX0R/?igshid=k8or8iv8pnry
Top News from EULAR 2018
Top News from EULAR 2018
All The Most Important News and Updates form the Annual European Congress of Rheumatology – EULAR 2018 AbbVie Presented Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis
June 12, 2018
AbbVie, a research-based global biopharmaceutical company, has presented new patient-reported outcome data from three Phase 3 trials evaluating upadacitinib, an…
View On WordPress